Oncolys BioPharma Inc. Logo

Oncolys BioPharma Inc.

Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.

4588 | T

Overview

Corporate Details

ISIN(s):
JP3202170001
LEI:
Country:
Japan
Address:
港区虎ノ門4−1−28虎ノ門タワーズオフィス10階
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncolys BioPharma Inc. is a biopharmaceutical company focused on developing breakthrough therapies and diagnostics for cancer and serious viral infections. The company's core strategy is centered on virology, specializing in the research, development, and commercialization of innovative drugs, particularly oncolytic viruses. Its pipeline addresses the full spectrum of cancer care, from early detection and prognostic tests to late-stage loco-regional and systemic treatments. A key product candidate is Telomelysin®, an oncolytic virus therapy. The company's business model involves advancing therapeutic candidates to early clinical proof-of-concept for licensing, with a mission to provide effective treatments that address significant unmet medical needs for patients and physicians.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 07:32
Regulatory News Service
確認書
Japanese 8.7 KB
2025-08-08 07:31
Interim Report
半期報告書-第22期(2025/01/01-2025/12/31)
Japanese 271.3 KB
2025-07-18 08:30
Registration Form
有価証券届出書(参照方式)
Japanese 877.6 KB
2025-03-31 03:16
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2025-03-28 02:16
Regulatory News Service
内部統制報告書-第21期(2024/01/01-2024/12/31)
Japanese 22.6 KB
2025-03-28 02:15
Annual Report
有価証券報告書-第21期(2024/01/01-2024/12/31)
Japanese 1.2 MB
2025-03-28 02:15
Regulatory News Service
確認書
Japanese 8.7 KB
2024-08-09 08:07
Interim Report
確認書
Japanese 8.8 KB
2024-08-09 08:07
Interim Report
半期報告書-第21期(2024/01/01-2024/12/31)
Japanese 262.0 KB
2024-06-14 08:00
Registration Form
有価証券届出書(参照方式)
Japanese 785.1 KB
2024-05-10 08:08
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-05-10 08:07
Quarterly Report
四半期報告書-第21期第1四半期(2024/01/01-2024/03/31)
Japanese 213.8 KB
2024-04-03 02:44
Post-Annual General Meeting Information
臨時報告書
Japanese 24.1 KB
2024-03-29 01:21
Registration Form
有価証券報告書-第20期(2023/01/01-2023/12/31)
Japanese 1.3 MB
2024-03-29 01:20
Registration Form
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Oncolys BioPharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncolys BioPharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncolys BioPharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

HELLENIC DYNAMICS PLC Logo
Cultivates and supplies THC-dominant medical cannabis for the European pharmaceutical market.
United Kingdom
HELD
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom
HEMO
HEM Pharma Inc. Logo
Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.
South Korea
376270
Hemp Health Spolka Akcyjna Logo
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland
HMP
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland
HRTIS
HERON THERAPEUTICS, INC. /DE/ Logo
Develops and commercializes therapies for acute care and oncology to manage pain and nausea.
United States of America
HRTX
Global manufacturer of carbapenem antibiotic APIs for regulated markets.
South Korea
106190
HIKMA Pharmaceuticals PLC Logo
Develops & markets affordable generic & specialty medicines for markets in NA, MENA, & Europe.
United Kingdom
HIK
HISAMITSU PHARMACEUTICAL CO.,INC. Logo
A global leader in transdermal drug delivery systems for OTC and prescription pain relief.
Japan
4530
HLB Genex, Inc. Logo
Develops custom enzymes & microbiome solutions for diagnostics, nutrition, and cosmetic markets.
South Korea
187420

Talk to a Data Expert

Have a question? We'll get back to you promptly.